As of May 25
| -0.06 / -2.90%|
The 4 analysts offering 12-month price forecasts for Eyepoint Pharmaceuticals Inc have a median target of 4.50, with a high estimate of 6.00 and a low estimate of 2.50. The median estimate represents a +123.88% increase from the last price of 2.01.
The current consensus among 4 polled investment analysts is to Buy stock in Eyepoint Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.